The PennZone

  • Home
  • Education
  • Non-profit
  • Technology
  • Business
  • Construction
  • Entertainment
  • Marketing
  • Health

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • Philadelphia's Own Reverend Jamie Knight Returns with "Award-Winning Love
  • Detained at 95: South Korea's Prosecution of a Religious Leader Draws International Alarm
  • Sara Abbas Receives "Eniochos" Charioteer Award at 2026 Who is Who International Awards
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • Search Is Broken. Curated Discovery Is the Future
  • 20 Ways to Save Money Running a Van
  • How Fortress Law Group Turned a DUI Arrest in Ohio Into a Full Acquittal at Trial
  • Breaking the Silence: Tour Sparks National Conversation on Men's Mental Health and Domestic Abuse
  • Mr. Hospital Bed Helps Home Care Buyers Find the Right Hospital Bed

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Class is in session: Black Beauty Block Party returns to Los Angeles for fourth annual festival
  • Heavy Duty Journal Surpasses 1000 Technical Articles for Diesel Technicians and Fleet Managers
  • Brett Furman Launches Ranks Grow
  • Philadelphia's Own Reverend Jamie Knight Returns with "Award-Winning Love
  • Kolbus Introduces the Next Step in Casemaking Efficiency
  • Florida Law Advisers, P.A. Named Best Divorce Firm of 2026 by Expert Law Attorneys
  • Sounds of LA County: 27 Parks.108 Concerts. One County
  • Only One Flight Stands Between Los Angeles Youth Leaders and a Life-Saving Mission in South Africa
  • Blueshirt Media Joins the Dazos Partner Program, Expanding HIPAA-Compliant AI Admissions Support for Behavioral Health Organizations
  • Stigma Across Borders: Concerns Grow Over Discrimination Against Shincheonji Members Abroad
  • Roohid Parast, J&J Scientist, Comments on New Psoriasis Biomarker Study
  • World Cup Crowds Are a Stress Test for America's Restrooms
  • Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
  • How Sacramento Families Are Using Private Autopsies to Protect Inheritances, Resolve Insurance Claims, and Find Closure
  • Los Angeles' Best Food: Food Journal Magazine Examines the Trends Shaping the City's Dining Scene
  • Landmark Construction Expands Glass, Glazing, and Commercial Remodeling Services Across Los Angeles County and Surrounding Areas
  • Imagen Golf Announces Strategic Partnership with The Back Nine of Yardley to Deliver World-Class Indoor Golf Instruction
  • Jazzin' On Ridge Returns for Its 6th Annual Celebration of Music, Culture, and Community
  • ENTOUCH Named Top 100 Inspiring Workplaces in North America for Third Consecutive Year
  • Rebecca L. Francis Receives Pennsylvania's Most Influential Leaders Award

Popular on PennZone

  • ReviewsAlly Launches Evidence-Based Review Platform for VPNs, Business Software, and Online Services
  • STO Foundation Launching June 29, 2026 to Advance the Global Tokenization Industry
  • Top 5 Most Reliable Used Vans in the UK in 2026
  • Turnstone Creative's Ashley Russo Serves as Emcee for United Way's 2026 NERC and Women's Summit
  • Allstream Energy Partners to Host 6th Executive Networking After 2026 Energy Projects Conference
  • Leimert Juneteenth Community Celebration Set for Friday, June 19, in Leimert Park Village
  • Justice Advisory Group Expands Federal Sentencing, Prison Preparation and Reentry Support Services
  • Sylvester Anthony III Introduces His Artist Journey with Debut Single "Cherish"
  • Freedomtech Solutions Launches the World's First Pre‑Installed Agentic AI Server — Instant, Sovereign, Infrastructure‑Native Intelligence
  • Compton to host first Juneteenth celebration with We Are Us Festival

Similar on PennZone

  • Roohid Parast, J&J Scientist, Comments on New Psoriasis Biomarker Study
  • Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
  • From DECA Finalist to Translational Scientist: Roohid Parast on Business Training in Biopharma
  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
  • Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
  • FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
  • Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us